Data from: A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy

Hanns Lochmüller, Anthony Behin, Yoseph Caraco, Heather Lau, Massimiliano Mirabella, Ivailo Tournev, Mark Tarnopolsky, Oksana Pogoryelova, Catherine Woods, Alexander Lai, Jinay Shah, Tony Koutsoukos, Alison Skrinar, Hank Mansbach, Emil Kakkis & Tahseen Mozaffar
Objective: To investigate the efficacy and safety of aceneuramic acid extended-release (Ace-ER), a treatment intended to replace deficient sialic acid, in patients with GNE myopathy. Methods: UX001-CL301 was a Phase 3, double-blind, placebo-controlled, randomized, international study evaluating the efficacy and safety of Ace-ER in patients with GNE Myopathy. Participants who could walk ≥200 meters in a 6-minute walk test at screening were randomized 1:1, and stratified by sex, to receive Ace-ER 6g/day or placebo for...

Registration Year

  • 2019
    1

Resource Types

  • Dataset
    1

Affiliations

  • New Bulgarian University
    1
  • Ultragenyx Pharmaceutical (United States)
    1
  • Newcastle University
    1
  • Institute of Myology
    1
  • McMaster University
    1
  • University of Ottawa
    1
  • University of California, Irvine
    1
  • Istituti di Ricovero e Cura a Carattere Scientifico
    1